(Q40415407)

20 September 2017

title

Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects (English)

1 reference

20 September 2017

1 reference

D Firmin

1

1 reference

20 September 2017

A M Roguedas

2

1 reference

20 September 2017

G Lemasson

3

1 reference

20 September 2017

J F Abgrall

4

1 reference

20 September 2017

L Misery

5

1 reference

20 September 2017

publication date

1 July 2008

1 reference

20 September 2017

1 reference

20 September 2017

volume

217

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

203-206

1 reference

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

20 September 2017

cites work

1 reference

Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.

21 January 2018

1 reference

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

21 January 2018

1 reference

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial

21 January 2018

1 reference

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

21 January 2018

1 reference

Disease concomitance in psoriasis.

21 January 2018

1 reference

Efalizumab for severe atopic dermatitis: a pilot study in adults

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000141958

1 reference

20 September 2017

1 reference